Baird Downgrades Human Genome (HGSI) to Neutral; Moving to Sidelines
Tweet Send to a Friend
Baird downgrades Human Genome (Nasdaq: HGSI) to Neutral, price target $3.
Baird analyst says, "While Albuferon met key efficacy endpoints ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Baird analyst says, "While Albuferon met key efficacy endpoints ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
